Navigation Links
Prostate Cancer Foundation announces new urine test for prostate cancer available
Date:9/26/2013

ine health screening measure for men of a certain age. What everyone does agree upon is the need for better markers of prostate cancer. To date there are no perfect biomarkers that identify only high-risk prostate cancer. But each year progress is made toward such a goal. Today, the University of Michigan's Department of Pathology MLabs will begin offering the MiPS urine test that is ultra specific for prostate cancer. The MiPS test scans urine samples for two molecular markers that are distinct to prostate cancer. One marker is a snippet of RNA made from a gene (PCA3) that is overactive in 95 percent of all prostate cancers. The second marker is RNA that is made only when two genes (TMPRSS2 and ERG) abnormally fuse. The presence of this fusion RNA in a man's urine is ultra specific for prostate cancer.

An ultra-specific test for prostate cancer

  • Dr. Scott Tomlins, MD, PhD, is an assistant professor of pathology and urology at the University of Michigan and a Safeway-Prostate Cancer Foundation Young Investigator. Tomlins co-discovered what is now commonly known as the TMPRSS2:ERG fusion. "The evidence shows that if TMPRSS2:ERG RNA is detectable at high levels in urine, a man likely has prostate cancer, whether or not his biopsy is positive for cancer," said Tomlins. (Because biopsies typically sample less than 1 percent of the prostate gland, cancers can be missed, even high-grade cancers.)

    A commercial urine test (PROGENSA PCA3) for PCA3, developed and marketed by the California-based biotech company Gen-Probe, gained FDA approval in 2012 for use in men who are considering repeat biopsy after an initially negative result. While a welcome development, research shows that the new urine test offered by MLabs that measures both PCA3 and TMPRSS2:ERG should improve a doctor's ability to stratify men suspected of having prostate cancer. In a study published in Science Translational Medicine, Tomlins and colleagues
    '/>"/>


Contact: Rebecca Levine
rlevine@pcf.org
310-570-4727
Prostate Cancer Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use
2. Study highlights possible new approach to prostate cancer treatment
3. Which Prostate Cancers Really Need Treatment?
4. Using big data to identify prostate cancers and best treatments
5. UCI chemists devise inexpensive, accurate way to detect prostate cancer
6. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
7. Soy and tomato combo may be effective in preventing prostate cancer
8. Particular DNA changes linked with prostate cancer development and lethality
9. Nonsurgical treatment turns back the clock, shrinks enlarged prostate
10. First genetic factor in prostate cancer prognosis identified
11. Landmark study describes prostate cancer metastasis switch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... , 31 de julio de 2015 La ... ) se celebrará por medio de BGI del 22 al 25 ... . Este año, la conferencia celebra su ... se ha convertido en una de las reuniones anuales más ... una de las reuniones más dinámicas, entusiastas y mejores a ...
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in ... ended March 31, 2010 . For clarity and consistency, the data ... Biometrics Division for such period.  The Company completed the sale of its ... , , ...
... have discovered that cheese can help preserve and enhance ... a carrier for probiotic bacteria. The research, published in ... daily consumption of probiotic cheese helps to tackle age-related ... the proportion of aged individuals in modern society makes ...
... 22q.11 deletion syndrome have identified key proteins that act ... essential to life; in animal studies, embryos without the ... of gestation. Although the findings do not ... shed light on the biological events that give rise ...
Cached Biology News:BIO-key(R) Reports First Quarter 2010 Financial Results 2BIO-key(R) Reports First Quarter 2010 Financial Results 3BIO-key(R) Reports First Quarter 2010 Financial Results 4BIO-key(R) Reports First Quarter 2010 Financial Results 5Cheese found to improve the immune response of the elderly 2Study finds protein that plays key role in early embryonic development 2
(Date:7/29/2015)... 29, 2015  AsureQuality and Ubiquitome have agreed ... applications in food and primary production sectors. The ... PCR device, the Freedom4. AsureQuality provides ... the supermarket shelf for producers, processors and Competent ... animal disease control and pest management and surveillance ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The third ... of combination products , in particular, drug/device combinations. The current system received a ... the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... 14 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today ... 2007. For the three-month period, the Company posted,revenue of ... Cash and cash,equivalents totaled $39.7 million at September 30, ... three priority product,candidates and most notably, after the quarter ...
... MELBOURNE, Australia, Nov. 14 Swiss experts have,abandoned ... (TST) favouring the,use of interferon-a release assays such ... (TB) infection prior to initiating,biological treatments (such as ... of the Swiss Medical Weekly, experts,advocate the use ...
... Calif., Nov. 13 AMDL, Inc. (Amex:,ADL) reported today ... Securities and,Exchange Commission indicating that its Form 10-QSB for ... filed by November 14, 2007. However,AMDL expects to file ... time,allotted by the Rules. Gary L. Dreher, President, stated: ...
Cached Biology Technology:TorreyPines Therapeutics Reports Third Quarter 2007 Results 2TorreyPines Therapeutics Reports Third Quarter 2007 Results 3TorreyPines Therapeutics Reports Third Quarter 2007 Results 4TorreyPines Therapeutics Reports Third Quarter 2007 Results 5TorreyPines Therapeutics Reports Third Quarter 2007 Results 6Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 2Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 3AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB 2
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Biology Products: